Fragile X-associated tremor/ataxia syndrome (FXTAS) is a late-onset neurodegenerative disease with motor, psychiatric, and cognitive manifestations that occurs in carriers of the fragile X mental retardation 1 (FMR1) gene premutations. This was a retrospective chart review of 196 individuals (127 men and 69 women) with FXTAS. Forty-six (23%) participants were cognitively impaired, of whom 19 (10%) had dementia. Risk factors for dementia were examined (CGG repeat size; alcohol, benzodiazepine, and opioid use; diabetes; hyperlipidemia; hypertension; hypothyroidism; obesity; sleep apnea; surgeries with general anesthesia; depression; family history of dementia). Thirteen individuals with FXTAS and dementia were then compared to 13 cognitively intact individuals matched on age, gender, and FXTAS stage. CGG repeat size was significantly higher (mean = 98.5, standard deviation [SD] = 22.2) in the dementia group, compared to the cognitively intact group (mean = 81.6, SD = 11.5; P = .0256). These results show that CGG repeat size is a risk factor for FXTAS dementia.
JuncosJLLazarusJTGraves-AllenE. New clinical findings in the fragile X-associated tremor ataxia syndrome (FXTAS). Neurogenetics. 2011;12(2):123–135.
2.
HagermanPJHagermanRJ. Fragile X-associated tremor/ataxia syndrome. Ann NY Acad Sci. 2015;1338:58–70.
3.
CoffeySMCookKTartagliaN. Expanded clinical phenotype of women with the FMR1 premutation. Am J Med Genet A. 2008;146A(8):1009–1016.
4.
Rodriguez-RevengaLMadrigalIPagonabarragaJ. Penetrance of FMR1 premutation associated pathologies in fragile X syndrome families. Eur J Hum Genet. 2009;17(10):1359–1362.
5.
SeritanALBourgeoisJASchneiderAMuYHagermanRJNguyenDV. Ages of onset of mood and anxiety disorders in fragile X premutation carriers. Curr Psychiatry Rev. 2013;9(1):65–71.
6.
SeritanALNguyenDVFariasST. Dementia in fragile X-associated tremor/ataxia syndrome (FXTAS): comparison with Alzheimer’s disease. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(7):1138–1144.
7.
GaneLWIosifAMFlynn-WilsonLVenturinoMHagermanRJSeritanAL. Assessment of patient and caregiver needs in fragile X-associated tremor/ataxia syndrome (FXTAS) by utilizing Q-sort methodology. Aging Ment Health. 2010;14(8):1000–1007.
8.
BourgeoisJBFarzinFBrunbergJA. Dementia with mood symptoms in a carrier of the fragile X-associated tremor/ataxia syndrome (FXTAS): clinical intervention with donepezil and venlafaxine. J Neuropsychiatry Clin Neurosci. 2006;18(2):171–177.
9.
BourgeoisJASeritanALCasillasM. Lifetime prevalence of mood and anxiety disorders in fragile X premutation carriers. J Clin Psychiatry. 2011;72(2):175–182.
10.
SeritanALSchneiderAOlichneyJMLeeheyMAAkinsRSHagermanRJ. Conversion disorder in women with the FMR1 premutation. Am J Med Genet A. 2009;149A(11):2501–2506.
11.
WangJYHesslDHagermanRJTassoneFRiveraSM. Age-dependent structural connectivity effects in fragile X premutation. Arch Neurol. 2012;69(4):482–489.
12.
WangJYHesslDSchneiderATassoneFHagermanRJRiveraSM. Fragile X-associated tremor/ataxia syndrome: influence of the FMR1 gene on motor fiber tracts in males with normal and premutation alleles. JAMA Neurol. 2013;70(10):1022–1029.
13.
LeeheyMABerry-KravisEMinSJ. Progression of tremor and ataxia in male carriers of the FMR1 premutation. Mov Disord. 2007;22(2):203–206.
14.
MooreCJDalyEMSchmitzM. A neuropsychological investigation of male premutation carriers of fragile X syndrome. Neuropsychologia. 2004;42(14):1934–1947.
15.
CornishKMLiLKoganCS. Age-dependent cognitive changes in carriers of the fragile X syndrome. Cortex. 2008;44(6):628–636.
16.
CornishKMKoganCSLiL. Lifespan changes in working memory in fragile X premutation carriers. Brain Cogn. 2009;69(3):551–558.
17.
CornishKMHockingDRMossSAKoganCS. Selective executive markers of at-risk profiles associated with the fragile X premutation. Neurology. 2011;77(7):618–622.
18.
GrigsbyJBregaAGJacquemontS. Impairment in the cognitive functioning of men with fragile X-associated tremor/ataxia syndrome (FXTAS). J Neurol Sci. 2006;248(1-2):227–233.
19.
SévinMKutalikZBergmanS. Penetrance of marked cognitive impairment in older male carriers of the FMR1 gene premutation. J Med Genet. 2009;46(12):818–824.
20.
GrigsbyJBregaAGLeeheyMA. Impairment of executive cognitive functioning in males with fragile X-associated tremor/ataxia syndrome. Mov Disord. 2007;22(5):642–650.
21.
MotherseadPKConradKHagermanRJGrecoCMHesslDTassoneF. GRAND ROUNDS: an atypical progressive dementia in a male carrier of the fragile X premutation: an example of fragile X-associated tremor/ataxia syndrome. Appl Neuropsychol. 2007;12(3):169–178.
22.
GonçalvesMRRCapelliLPNitriniR. Atypical clinical course of FXTAS: rapidly progressive dementia as the major symptom. Neurology. 2007;68(21):1864–1866.
AllenEGHunterJERusinM. Neuropsychological findings from older premutation carriers and their noncarrier siblings from families with fragile X syndrome. Neuropsychology. 2011;25(3):404–411.
25.
TassoneFAdamsJBerry-KravisEM. CGG correlates with age of onset of motor signs of the fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet B Neuropsychiatr Genet. 2007;144B(4):566–569.
JenkinsECTassoneFYeL. Reduced telomere length in older men with premutation alleles of the fragile X mental retardation 1 gene. Am J Med Genet A. 2008;146A(12):1543–1546.
28.
BacalmanSFarzinFBourgeoisJA. Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia. J Clin Psychiatry. 2006;67(1):87–94.
29.
BregaAGReynoldsABennettRE. Functional status of men with the fragile X premutation, with and without the tremor/ataxia syndrome (FXTAS). Int J Geriatr Psychiatry. 2009;24(10):1101–1109.
30.
Al-HintiJTNaganNHarikSI. Fragile X premutation in a woman with cognitive impairment, tremor, and history of premature ovarian failure. Alzheimer Dis Assoc Disord. 2007;21(3):262–264.
31.
KarmonYGadothN. Fragile X associated tremor/ataxia syndrome (FXTAS) with dementia in a female harbouring FMR1 premutation. J Neurol Neurosurg Psychiatry. 2008;79(6):738–789.
32.
Rodriguez-RevengaLPagonabarragaJGomez-AnsonB. Motor and mental dysfunction in mother-daughter transmitted FXTAS. Neurology. 2010;75(15):1370–1376.
TassoneFGrecoCMHunsakerMR. Neuropathological, clinical, and molecular pathology in female fragile X premutation carriers with and without FXTAS. Genes Brain Behav. 2012;11(5):577–585.
35.
AlexopoulosGSMeyersBSYoungRC. The course of geriatric depression with “reversible dementia”: a controlled study. Am J Psychiatry. 1993;150(11):1693–1699.
36.
ButtersMABeckerJTNebesRD. Changes in cognitive functioning following treatment of late-life depression. Am J Psychiatry. 2000;157(12):1949–1954.
37.
van DuijnCMClaytonDGChandraV. Interaction between genetic and environmental risk factors for Alzheimer’s disease: a reanalysis of case-control studies. Genet Epidemiol. 1994;11(6):539–551.
JacquemontSHagermanRJLeeheyM. Fragile X premutation tremor/ataxia syndrome: molecular, clinical, and neuroimaging correlates. Am J Hum Genet. 2003;72(4):869–878.
40.
HamlinALiuYNguyenDV. Sleep apnea in fragile X premutation carriers with and without FXTAS. Am J Med Genet B Neuropsychiatr Genet. 2011;156B(8):923–928.
41.
HamlinASukharevDCamposL. Hypertension in FMR1 premutation males with and without fragile X-associated tremor/ataxia syndrome (FXTAS). Am J Med Genet. 2012;158A(6):1304–1309.
42.
DaviglusMLPlassmanMLPirzadaA. Risk factors and preventive interventions for Alzheimer disease: state of the science. Arch Neurol. 2011;68(9):1185–1190.
43.
BarnesDYaffeK. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10(9):819–828.
44.
YaffeKLaffanAMHarrisonSL. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA. 2011;306(6):613–619.
45.
KawadaTOtsukaTNakamuraYKonY. Relationship between sleep-disordered breathing and metabolic syndrome after adjustment with cardiovascular risk factors. Diabetes Metab Syndr. 2015;10(2):92–95.
46.
EdwardsKMKamatRTomfohrLMAncoli-IsraelSDimsdaleJE. Obstructive sleep apnea and neurocognitive performance: the role of cortisol. Sleep Med. 2014;15(1):27–32.
47.
SeritanALOrtigasMSeritanSBourgeoisJAHagermanRJ. Psychiatric disorders associated with FXTAS. Curr Psychiatry Rev. 2013;9(1):59–64.
48.
KoganCSTurkJHagermanRJCornishKM. Impact of the fragile X mental retardation 1 (FMR1) gene premutation on neuropsychiatric functioning in adult males without fragile X-associated tremor/ataxia syndrome: a controlled study. Am J Med Genet B Neuropsychiatr Genet. 2008;147B(6):859–872.
49.
FirstMBSpitzerRLGibbonMWilliamsJBW. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Patient Edition (SCID-I/P). New York, NY: Biometrics Research, New York State Psychiatric Institute; 2002.
50.
American Psychiatric Association. American Psychiatric Association: Diagnostic Criteria from DSM-IV-TR. Washington, DC: American Psychiatric Press, Inc; 2000:98.
51.
National Alzheimer’s Coordinating Center. National Alzheimer’s Coordinating Center User Data Set. Seattle, WA: NACC; 2006.
52.
StoreyJDTaylorJESiegmundD. Strong control, conservative point estimation, and simultaneous conservative consistency of false discovery rates: a unified approach. JR Statist Soc B. 2004;66(1):187–205.
53.
OlichneyJMChanSWongL. Abnormal N400 word repetition effects in fragile X-associated tremor/ataxia syndrome. Brain. 2010;133(pt 5):1438–1450.
54.
YangJCChiLTeichholtzS. ERP abnormalities elicited by word repetition in fragile X-associated tremor/ataxia syndrome (FXTAS) and amnestic MCI. Neuropsychologia. 2014;63:34–42.
American Psychiatric Association. Diagnostic Criteria from DSM-5. Washington, DC: American Psychiatric Press, Inc; 2013:299–320
57.
MortimerJABorensteinARGoscheKMSnowdonDA. Very early detection of Alzheimer pathology and the role of brain reserve in modifying its clinical expression. J Geriatr Psychiatry Neurol. 2005;18(4):218–223.
58.
RobertsJEBaileyDJrMankowskiJ. Mood and anxiety disorders in females with the FMR1 premutation. Am J Med Genet Neuropsychiatr Genet. 2009;150B(1):130–139.
59.
RossCATabriziSJ. Huntington’s disease: from molecular pathogenesis to clinical treatment. Lancet Neurol. 2011;10(1):83–98.
60.
ApartisEBlancherAMeissnerWG. FXTAS: new insights and the need for revised diagnostic criteria. Neurology. 2012;79(18):1898–1907.
61.
AnangJBMGagnonJFBertrandJA. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology. 2014;83(14):1253–1260.
ViticchiGFalsettiLVernieriF. Apolipoprotein E genotype and cerebrovascular alterations can influence conversion to dementia in patients with mild cognitive impairment. J Alzheimers Dis. 2014;41(2):401–410.
64.
SacuiuSInselPSMuellerS. Chronic depressive symptomatology in mild cognitive impairment is associated with frontal atrophy rate which hastens conversion to Alzheimer dementia. Am J Geriatr Psychiatry. 2016;24(2):126–135.
65.
ChungJKPlitmanENakajimaS. Depressive symptoms and small hippocampal volume accelerate the progression to dementia from mild cognitive impairment. J Alzheimers Dis. 2015;49(3):743–754.
66.
SilvaFRodriguez-RevengaLMadrigalIAlvarez-MoraMIOlivRMiláM.High apolipoprotein E4 allele frequency in FXTAS patients. Genet Med. 2013;15(8):639–642.
67.
ShelineYIGadoMHKraemerHC. Untreated depression and hippocampal volume loss. Am J Psychiatry. 2003;160(8):1516–1518.
68.
HallDABerry-KravisEHagermanRJHagermanPJRiceCDLeeheyMA. Symptomatic treatment in the fragile X-associated tremor/ataxia syndrome. Mov Disord. 2006;21(10):1741–1744.
69.
SeritanALNguyenDVMuY. Memantine for fragile X-associated tremor/ataxia syndrome (FXTAS): a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2014;75(3):264–271.
70.
HagermanRJHallDACoffeyS. Treatment of fragile X-associated tremor ataxia syndrome (FXTAS) and related neurological problems. Clin Interv Aging. 2008;3(4):251–262.
